A triple combination of chidamide + celecoxib + anti-CTLA-4 antibody significantly reduced tumor volume, with primary tumor eradication in 6 out of 8 mice, and 100% survival at day 60 after tumor implantation (Fig. 4C–E,H). Here, CTLA4 is linked to neoplasm.